Durvalumab vs Mycophenolate Mofetil Hydrochloride

Durvalumab vs Mycophenolate Mofetil Hydrochloride: Overview

This comparison examines the pharmacological differences between Durvalumab and Mycophenolate Mofetil Hydrochloride.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab — 17 days.

Chemical Properties

Type: Durvalumab — Antibody; Mycophenolate Mofetil Hydrochloride — Small molecule.